Gilead Symposia at AIDS 2024

Developed under the direction and sponsorship of Gilead Sciences, Inc.

At the AIDS 2024 congress, Gilead Sciences hosted two interactive and engaging symposia, discussing the unmet needs and health inequities that exist in HIV prevention globally, as well as factors that can help people with HIV achieve durable viral suppression and long-term success.

Symposium 1: How treatment selection can support long-term success to manage HIV

Treatment is integral in paving a pathway to long-term success at an individual level and pivotal in supporting the continuum of care from a public health perspective.

This collaborative symposium explored five treatment selection factors to help people with HIV and healthcare systems achieve long-term success. Together, these factors support a comprehensive approach to HIV management, helping diverse populations of people with HIV accomplish their goals and achieve long-term success.

Attendees heard the perspectives of experienced healthcare professionals and the lived experiences of community members, with discussion focused on how each factor can help guide confident decision-making in the clinic and in the health systems to fight the HIV epidemic.

This interactive, topical rotation and panel discussion covered five treatment selection factors for long-term success:

• Rapid initiation
• Safety and tolerability
• High barrier to resistance
• Person-centred
• Treatment experience

Hear more about the discussions from the meeting Chair, David Malebranche

Listen to our community members, Kim Canady and Gerben Grimmius, give their perspectives on the five criteria for long-term success

Hear from our community panellists, Kim Canady and Gerben Grimmius, on the importance of Undetectable = Untransmittable (U=U) to them and the community they represent

Symposium 2: What’s Preventing Us From Preventing: Pushing Together Towards the UNAIDS 2030 HIV Prevention Goals

Watch a summary of the symposium highlights below, as our international panel of individuals with lived experience and subject matter experts explored the necessity of system changes; emphasized the importance of person-centered care; and highlighted the crucial use of creative solutions to address health inequities, unmet needs, and stigma. Vitally, these discussions aimed to inspire collective efforts from all attendees towards achieving the UNAIDS 2030 HIV prevention targets and helping end the HIV epidemic together.

A combination of moderator-led panel discussion, keynote presentations, and data slide-supplemented debate were featured in a varied agenda:

• Putting People First: Personal Stories from Individuals with Lived Experience
• The UNAIDS 95% Prevention Target and its Increasingly Important Role in Ending the HIV Epidemic
• Addressing Barriers to Prevention
• Key Issues Associated with Prevention: Moderated Point-Counterpoint Debate
• Call to Action to Achieve the UNAIDS 2023 HIV Prevention Targets

Hear more about this event from the meeting Chair, Senior Vice President of Public Affairs at Gilead Sciences, Alex Kalomparis

Learn about what person-centred care means to Harold Phillips, Deputy Director of Programs for NMAC, in Washington D.C., USA, and what can be done to ensure HIV prevention is viewed as a public health priority in the USA and globally

Listen to Vanessa Apea from Queen Mary University, London, UK, discuss how we can prioritise HIV prevention services among adolescent girls and young women

These non-promotional meetings were organised and funded by Gilead Sciences, Inc.

IHQ-UNB-6389 | September 2024